Almost half of patients diagnosed with ANCA-associated vasculitis (AAV) showed neurological symptoms in a single-site, retrospective study from India. But…
Patricia Inacio, PhD
Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Patricia Inacio, PhD
ANCA-associated vasculitis (AAV) patients with renal involvement have higher blood levels of certain small vesicles than either patients without…
Researchers say an important clinical assessment is determining whether ANCA-associated vasculitis patients who need dialysis at disease onset, due…
Levels of rheumatoid factor — an antibody against healthy tissue found in some autoimmune diseases — appear to separate…
Inflammatory Proteins May Serve as Biomarkers of Early Disease, Kidney Damage in AAV, Study Suggests
Determining the levels of interleukins in the blood, specifically IL-10 and IL-33, may help identify people with early systemic…
Cardiac tamponade, the buildup of fluid in the space surrounding the heart, revealed a case of eosinophilic granulomatosis with…
People with ANCA-associated vasculitis (AAV) experience much worse fatigue than the general population, and although this eases in…
The U.S. Food and Drug Administration (FDA) has granted Priority Review to Rituxan (rituximab) in combination with glucocorticoids for…
ANCA-associated vasculitis patients in Korea have a high prevalence of thyroid dysfunction, with the condition affecting mainly those who…
InflaRx will soon launch a Phase 2 clinical trial in Europe to assess the safety and effectiveness of IFX-1 —…